# InflaRx N.V. (IFRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $1.68 (+3.40%)

> InflaRx N.V. is a clinical-stage biopharmaceutical company developing innovative anti-inflammatory therapeutics by targeting the complement system, specifically the C5a pathway and C5aR receptor. Headquartered in Jena, Germany, and founded in 2007, the company applies proprietary anti-C5a and C5aR technologies to discover and develop first-in-class or best-in-class inhibitors for treating life-threatening and debilitating inflammatory diseases. The company's lead program, vilobelimab, is a first-in-class monoclonal anti-C5a antibody designed to block inflammatory mediators while preserving the immune system's membrane attack complex defense mechanism. InflaRx's pipeline includes treatments for conditions such as pyoderma gangrenosum, severe COVID-19, cutaneous squamous cell carcinoma, and hidradenitis suppurativa. The company is also developing INF904, an orally available small molecule C5aR inhibitor targeting chronic inflammatory conditions. By selectively modulating the complement cascade rather than broadly suppressing immune function, InflaRx's approach aims to address multiple autoimmune and inflammatory diseases with improved safety profiles.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/IFRX)